InSilico Medicine Cayman TopCo (FRA:O15) Beneish M-Score: 18.91 (As of Aug. 27, 2026) — 116% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O15 InSilico Medicine Cayman TopCo FRA:O15
20 GF Score
Price €5.25
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo Beneish M-Score?

InSilico Medicine Cayman TopCo FRA:O15 +3.96% 20 Beneish M-Score is 18.91 as of Aug. 27, 2026, which is 116% above its 10-year median of 8.76. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 2,640 Software companies, InSilico Medicine Cayman TopCo ranks worse than 98.83% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 18.91 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for InSilico Medicine Cayman TopCo's Beneish M-Score or its related term are showing as below:

FRA:O15' s Beneish M-Score Range Over the Past 10 Years
Min: -1.39   Med: 8.76   Max: 18.91
Current: 18.91

During the past 4 years, the highest Beneish M-Score of InSilico Medicine Cayman TopCo was 18.91. The lowest was -1.39. And the median was 8.76.

InSilico Medicine Cayman TopCo Beneish M-Score Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo Beneish M-Score Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 -1.39 18.91

InSilico Medicine Cayman TopCo Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial 0.00 0.00 -1.39 0.00 18.91

FRA:O15 vs MSFT, ORCL, PLTR: Beneish M-Score Comparison

For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InSilico Medicine Cayman TopCo Beneish M-Score vs Software Industry

For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where InSilico Medicine Cayman TopCo's Beneish M-Score falls into.


FRA:O15
20GF Score
InSilico Medicine Cayman TopCo FRA:O15
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of InSilico Medicine Cayman TopCo for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 27.1799+0.528 * 1.1086+0.404 * 0.6457+0.892 * 0.5859+0.115 * 1.4673
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3484+4.679 * -0.562368-0.327 * 0.0138
=18.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €18.41 Mil.
Revenue was €48.03 Mil.
Gross Profit was €39.15 Mil.
Total Current Assets was €405.03 Mil.
Total Assets was €418.45 Mil.
Property, Plant and Equipment(Net PPE) was €11.25 Mil.
Depreciation, Depletion and Amortization(DDA) was €4.08 Mil.
Selling, General, & Admin. Expense(SGA) was €7.40 Mil.
Total Current Liabilities was €28.95 Mil.
Long-Term Debt & Capital Lease Obligation was €3.47 Mil.
Net Income was €-300.88 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €-65.56 Mil.
 Total Receivables was €1.16 Mil.
Revenue was €81.97 Mil.
Gross Profit was €74.09 Mil.
Total Current Assets was €127.41 Mil.
Total Assets was €137.52 Mil.
Property, Plant and Equipment(Net PPE) was €9.01 Mil.
Depreciation, Depletion and Amortization(DDA) was €5.77 Mil.
Selling, General, & Admin. Expense(SGA) was €9.36 Mil.
Total Current Liabilities was €770.56 Mil.
Long-Term Debt & Capital Lease Obligation was €1.01 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18.41 / 48.028) / (1.156 / 81.971)
=0.383318 / 0.014103
=27.1799

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(74.086 / 81.971) / (39.154 / 48.028)
=0.903807 / 0.815233
=1.1086

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (405.033 + 11.245) / 418.445) / (1 - (127.406 + 9.013) / 137.522)
=0.005179 / 0.008021
=0.6457

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=48.028 / 81.971
=0.5859

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.773 / (5.773 + 9.013)) / (4.077 / (4.077 + 11.245))
=0.390437 / 0.266088
=1.4673

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(7.398 / 48.028) / (9.364 / 81.971)
=0.154035 / 0.114236
=1.3484

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.471 + 28.945) / 418.445) / ((1.01 + 770.558) / 137.522)
=0.077468 / 5.610506
=0.0138

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-300.878 - 0 - -65.558) / 418.445
=-0.562368

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

InSilico Medicine Cayman TopCo has a M-score of 18.84 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 18.91 mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a Beneish M-Score of 18.91 as of Aug. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on InSilico Medicine Cayman TopCo and its competitors. This is 116% above median its historical median of 8.76. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #2609 out of 2640 companies in the Software industry, placing it in the top 98.8%.
Is InSilico Medicine Cayman TopCo's Beneish M-Score too high?
InSilico Medicine Cayman TopCo's current Beneish M-Score of 18.91 is 116% above median its 10-year median of 8.76. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #2609 out of 2640 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Beneish M-Score compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #2609 out of 2640 companies for Beneish M-Score. This places InSilico Medicine Cayman TopCo in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Software company?
A good Beneish M-Score depends on the Software industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Beneish M-Score is 18.91, which is 116% above median its own 10-year median of 8.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current Beneish M-Score of 18.91. The current Beneish M-Score is 18.91, which is 116% above median its 10-year median of 8.76. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current Beneish M-Score is 18.91 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Other Exchanges 03696:Hong Kong
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score

Get the complete analysis for FRA:O15

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price